- Tytuł:
-
Mechanizm oporności na leki platynowe oraz strategie pokonywania tego zjawiska
The mechanism of resistance to platinum drugs and strategies to overcome this phenomenon - Autorzy:
-
Weiss-Gradzińska, W.
Krzempek, W.
Trynda-Lemiesz, L. - Powiązania:
- https://bibliotekanauki.pl/articles/172324.pdf
- Data publikacji:
- 2013
- Wydawca:
- Polskie Towarzystwo Chemiczne
- Tematy:
-
leki platynowe
oporność lekowa
leczenie nowotworów
influx
efflux
nanorurki węglowe
cisplatyna
platinum drugs
drug resistance
cancer therapy
carbon nanotubes
cisplatin - Opis:
- Platinum drugs belong to one of the oldest [2] and best investigated groups of cytotoxic drugs. On account of their high efficacy and alkylating-like action [14] they are used in a treatment of various types of neoplasms [3–5]. Despite investigators’ best efforts survival time of patients diagnosed with cancer is still short. Responsible for the fact is high toxicity of used therapeutic methods and development of resistance to them [3–5, 19]. In this paper authors review reasons behind decreased sensitivity of neoplastic cells to platinum treatment and discuss the newest promising trends in its overcoming. Due to different properties of neoplastic cells, availability of a chemotherapeutic agent inside a tumour is limited [9–12]. Moreover continuous development of resistance to platinum drugs further decreases their cellular concentration and inactivates their functions. Also owing to increased activity of DNA repair systems, higher tolerance to genome deformations and numerous mechanisms that lead to impaired apoptosis, drug efficacy is reduced [3-5, 19]. In order to increase a potency of platinum agents new therapeutic strategies are investigated. Coadministration with resistance modulators [20, 22, 23] and combination therapy with other antineoplastic drugs [8, 24–30] have already proved their effectiveness. Additionally, newer generations of platinum drugs are developed [15–18]. Mostly platinum(IV) prodrug complexes often releasing axial ligands with their own pharmacological action [5, 6, 31], but also multi-nuclear platinum compounds that form more complex DNA-adducts [32–35]. Other strategies include the development of innovative dosage forms such as single walled carbon nanotubes (SWCNTs), multiwalled carbon nanotubes (MWCNTs) [38, 39] or encapsulation [36, 37]. Finally utilisation of oncolytic viruses could be a way to selectively destroy neoplastically transformed cells [40].
- Źródło:
-
Wiadomości Chemiczne; 2013, 67, 11-12; 1105-1128
0043-5104
2300-0295 - Pojawia się w:
- Wiadomości Chemiczne
- Dostawca treści:
- Biblioteka Nauki
Artykuł